Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020
Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020
SUMMARY
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 10 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Uveal Melanoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Pancreatic Cancer, Retinitis Pigmentosa (Retinitis) and Triple-Negative Breast Cancer (TNBC).
The latest report Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 10 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Uveal Melanoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Pancreatic Cancer, Retinitis Pigmentosa (Retinitis) and Triple-Negative Breast Cancer (TNBC).
The latest report Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Elsalys Biotech SA
F. Hoffmann-La Roche Ltd
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Meryx Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rgenix Inc
SignalChem Lifesciences Corp
TamRx LLC
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2019: Dong-A ST's investigational drug posts positive study results
Apr 03, 2019: Rgenix presents pre-clinical data on RGX-019 at the 2019 AACR Annual Meeting
Apr 01, 2019: Rgenix to present abstract on RGX-019 at the 2019 AACR Annual Meeting
Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for Immunotherapy of Cancer's 33rd annual meeting
Dec 29, 2017: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Elsalys Biotech SA
F. Hoffmann-La Roche Ltd
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Meryx Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rgenix Inc
SignalChem Lifesciences Corp
TamRx LLC
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2019: Dong-A ST's investigational drug posts positive study results
Apr 03, 2019: Rgenix presents pre-clinical data on RGX-019 at the 2019 AACR Annual Meeting
Apr 01, 2019: Rgenix to present abstract on RGX-019 at the 2019 AACR Annual Meeting
Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for Immunotherapy of Cancer's 33rd annual meeting
Dec 29, 2017: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Celldex Therapeutics Inc, H1 2020
Pipeline by Celon Pharma SA, H1 2020
Pipeline by Dong-A Socio Holdings Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Elsalys Biotech SA, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by HEC Pharm Co Ltd, H1 2020
Pipeline by Hope Biosciences Inc, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Meryx Inc, H1 2020
Pipeline by Novithera SAS, H1 2020
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Pipeline by Qurient Co Ltd, H1 2020
Pipeline by Rgenix Inc, H1 2020
Pipeline by SignalChem Lifesciences Corp, H1 2020
Pipeline by TamRx LLC, H1 2020
Dormant Projects, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Celldex Therapeutics Inc, H1 2020
Pipeline by Celon Pharma SA, H1 2020
Pipeline by Dong-A Socio Holdings Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Elsalys Biotech SA, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by HEC Pharm Co Ltd, H1 2020
Pipeline by Hope Biosciences Inc, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Meryx Inc, H1 2020
Pipeline by Novithera SAS, H1 2020
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Pipeline by Qurient Co Ltd, H1 2020
Pipeline by Rgenix Inc, H1 2020
Pipeline by SignalChem Lifesciences Corp, H1 2020
Pipeline by TamRx LLC, H1 2020
Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Elsalys Biotech SA
F. Hoffmann-La Roche Ltd
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Meryx Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rgenix Inc
SignalChem Lifesciences Corp
TamRx LLC
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Elsalys Biotech SA
F. Hoffmann-La Roche Ltd
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Meryx Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rgenix Inc
SignalChem Lifesciences Corp
TamRx LLC
